8-K: Tonix Pharmaceuticals Engages Rho to Support FDA Submission for Fibromyalgia Drug Tonmya

Tonix Pharmaceuticals has partnered with Rho, Inc. to assist in the New Drug Application submission to the FDA for Tonmya, a potential treatment for fibromyalgia.

Summary

• Tonix Pharmaceuticals has engaged Rho, a contract research organization, to support the preparation and submission of a New Drug Application (NDA) to the FDA for Tonmya.
• Tonmya is a sublingual tablet formulation of cyclobenzaprine hydrochloride intended for the management of fibromyalgia.
• The company plans to meet with the FDA in the first half of 2024 and submit the NDA in the second half of 2024.
• Tonmya has shown statistically significant results in two Phase 3 clinical trials, reducing daily pain compared to placebo.
• Fibromyalgia affects an estimated 6 to 12 million adults in the U.S., and Tonmya is being developed as a potential first-line, non-opioid analgesic.

Sentiment

Score: 7

Explanation: The document is positive due to the progress in the development of Tonmya and the engagement of Rho for the NDA submission. However, there are still risks associated with regulatory approval and commercialization.

Positives

• Tonmya has completed two positive Phase 3 trials, showing statistically significant pain reduction compared to placebo.
• The engagement of Rho is a positive step towards the NDA submission.
• Tonmya has potential market exclusivity until 2034/2035 due to existing patents.
• The company intends to meet with the FDA in the first half of 2024, indicating progress in the regulatory process.
• Tonmya is being developed as a non-opioid analgesic, addressing a need for alternative pain management options.

Risks

• The company faces risks related to obtaining FDA approval for Tonmya.
• There are risks associated with the successful marketing of Tonmya.
• The company's success depends on the timing and progress of clinical development.
• The company may require additional financing.
• There are risks related to patent protection and litigation.
• The company faces competition from other pharmaceutical companies.
• There are uncertainties of government or third party payor reimbursement.

Future Outlook

Tonix plans to meet with the FDA in the first half of 2024 and submit the NDA for Tonmya in the second half of 2024. The company is also developing other drugs for various conditions.

Management Comments

• Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, stated that they are excited by the positive Phase 3 study results of Tonmya and look forward to Rho's support in preparing the NDA.
• Tara Gladwell, President and COO at Rho, expressed delight in supporting Tonix and their Tonmya program, hoping it will result in a new treatment for fibromyalgia sufferers.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the area of pain management and central nervous system disorders. The development of Tonmya addresses the need for new treatments for fibromyalgia, a condition with limited effective options.

Comparison to Industry Standards

• The successful completion of two Phase 3 trials for Tonmya is a positive sign, as many drugs fail at this stage.
• The planned NDA submission in the second half of 2024 is a typical timeline for a drug with positive Phase 3 results.
• The engagement of a CRO like Rho is a common practice in the pharmaceutical industry to support regulatory submissions.
• Tonix's focus on a non-opioid analgesic aligns with the industry trend of seeking alternatives to opioids for pain management.
• The market exclusivity expected until 2034/2035 is a significant advantage, similar to other patented drugs in the market.

Stakeholder Impact

• Shareholders may view this announcement positively due to the progress in Tonmya's development.
• Patients suffering from fibromyalgia may benefit from a new treatment option.
• Employees of Tonix may be positively impacted by the company's progress.
• The partnership with Rho may benefit both companies.

Next Steps

• Tonix intends to meet with the FDA in the first half of 2024.
• The company plans to submit the NDA for Tonmya in the second half of 2024.
• A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024.

Key Dates

Keywords

Tonmya, Fibromyalgia, NDA, FDA, Rho, Clinical Trials, Pharmaceuticals, Pain Management, Cyclobenzaprine, Sublingual Tablet